NCT00027677View on ClinicalTrials.gov

Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

February 29, 2004

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

halofuginone hydrobromide

Trial Locations (3)

B-3000

U.Z. Gasthuisberg, Leuven

3000 CA

University Hospital - Rotterdam Dijkzigt, Rotterdam

3008 AE

Daniel Den Hoed Cancer Center at Erasmus Medical Center, Rotterdam

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00027677 - Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors | Biotech Hunter | Biotech Hunter